Animal Food Ingredient Consultation; Draft Guidance for Industry; Availability, 65368-65369 [2024-17778]
Download as PDF
65368
Federal Register / Vol. 89, No. 154 / Friday, August 9, 2024 / Notices
guidances-drugs, https://www.fda.gov/
vaccines-blood-biologics/guidancecompliance-regulatory-informationbiologics/biologics-guidances, https://
www.fda.gov/regulatory-information/
search-fda-guidance-documents, or
https://www.regulations.gov.
Dated: August 6, 2024.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2024–17771 Filed 8–8–24; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2024–D–2978]
Animal Food Ingredient Consultation;
Draft Guidance for Industry;
Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of availability.
The Food and Drug
Administration (FDA or Agency) is
announcing the availability of draft
guidance for industry #294 entitled
‘‘Animal Food Ingredient Consultation
(AFIC).’’ This draft guidance describes
FDA’s interim AFIC process and
explains one way FDA intends to work
with firms that are developing animal
food ingredients after the Memorandum
of Understanding (MOU) with the
Association of American Feed Control
Officials (AAFCO) expires on October 1,
2024, and while FDA evaluates the
animal Food Additive Petition and
generally recognized as safe (GRAS)
Notification programs. The new AFIC
process will provide an additional way
for engagement with FDA regarding
ingredients for which firms may
otherwise have used the AAFCO
ingredient definition process. AFIC will
help FDA identify any potential safety
concerns associated with such
ingredients. The AFIC process will also
allow for public awareness of and input
on such ingredients. In addition, this
draft guidance describes FDA’s
enforcement policy for certain
ingredients assessed using the AFIC
process.
ddrumheller on DSK120RN23PROD with NOTICES1
SUMMARY:
Submit either electronic or
written comments on the draft guidance
by September 9, 2024 to ensure that the
Agency considers your comment on this
draft guidance before it begins work on
the final version of the guidance.
ADDRESSES: You may submit comments
on any guidance at any time as follows:
DATES:
VerDate Sep<11>2014
19:21 Aug 08, 2024
Jkt 262001
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2024–D–2978 for ‘‘Animal Food
Ingredient Consultation (AFIC).’’
Received comments will be placed in
the docket and, except for those
submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Dockets Management Staff between 9
a.m. and 4 p.m., Monday through
Friday, 240–402–7500.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Dockets Management
Staff. If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://
www.govinfo.gov/content/pkg/FR-201509-18/pdf/2015-23389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852, 240–402–7500.
You may submit comments on any
guidance at any time (see 21 CFR
10.115(g)(5)).
Submit written requests for single
copies of the guidance to the Policy and
Regulations Staff, Center for Veterinary
Medicine, Food and Drug
Administration, 7500 Standish Pl.,
Rockville, MD 20855. Send one selfaddressed adhesive label to assist that
office in processing your requests. See
the SUPPLEMENTARY INFORMATION section
for electronic access to the draft
guidance document.
FOR FURTHER INFORMATION CONTACT:
Charlotte Conway, Center for Veterinary
Medicine, Food and Drug
Administration, 7519 Standish Pl.,
Rockville, MD 20855, 240–402–6768,
Charlotte.Conway@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
FDA is announcing the availability of
draft guidance for industry #294 entitled
‘‘Animal Food Ingredient Consultation
(AFIC).’’ This draft guidance describes
FDA’s interim AFIC process and
explains one way FDA intends to work
with firms that are developing animal
E:\FR\FM\09AUN1.SGM
09AUN1
ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 89, No. 154 / Friday, August 9, 2024 / Notices
food ingredients after the MOU with
AAFCO expires on October 1, 2024, and
while FDA evaluates the animal Food
Additive Petition and GRAS
Notification programs. In addition, this
draft guidance describes FDA’s
enforcement policy for certain
ingredients reviewed using the AFIC
process.
The Food, Drug, and Cosmetic Act
(FD&C Act) gives FDA the authority to
regulate substances used in animal food,
including substances that are food
additives and substances that are GRAS
for their intended uses in food.1
Since 1920, AAFCO has maintained
the AAFCO Official Publication (OP),
which contains, among other things, a
comprehensive list of animal food
ingredients, including FDA-approved
food additives, substances that are
GRAS for one or more intended uses,
and animal food ingredient definitions
established through the AAFCO
Ingredient Definition Request Process.
In 2007, FDA entered into an MOU,
225–07–7001, with AAFCO that
outlines how FDA would provide its
scientific and technical expertise to
AAFCO in reviewing requested
ingredient definitions requested by
industry or AAFCO. This MOU has been
renewed and revised several times. The
current MOU 225–07–7001 expires in
October 2024 and will not be renewed.
See https://www.fda.gov/animalveterinary/animal-food-feeds/fda-letterstakeholders-acknowledgment-expiringfda-aafco-mou.
Following the expiration of the MOU,
FDA plans to evaluate its animal Food
Additive Petition and GRAS
Notification programs to determine if
changes are needed to promote the
efficient development and review of
new animal food ingredients.
We are issuing this draft guidance to
announce the creation of the AFIC
process to provide an additional way for
engagement with FDA regarding animal
food ingredients following the
expiration of the MOU with AAFCO and
during this interim evaluation period.
AFIC will provide a process that will
help FDA be aware of new ingredients
that are marketed in interstate
commerce and any potential safety
concerns associated with such
ingredients. AFIC will serve to provide
a baseline of safety information
available about such an ingredient,
making it easier to compare
developments that might occur during
marketing. AFIC also will give FDA an
opportunity to discuss any potential
safety concerns with the developer,
1 See
21 CFR part 570, subpart E.
VerDate Sep<11>2014
19:21 Aug 08, 2024
Jkt 262001
ideally before the ingredient is
marketed.
AFIC also will allow for public
awareness of and input on ingredients
for which FDA is providing
consultation. Our goal is to support
innovation in animal food technologies
while maintaining as our priority the
production of safe animal food.
FDA generally does not intend to
initiate enforcement action with respect
to the food additive approval
requirements of the FD&C Act for an
ingredient, or animal food containing
such ingredient, if such an ingredient
has been reviewed and is the subject of
a ‘‘consultation complete’’ letter under
the AFIC process, and is used in
accordance with the ‘‘consultation
complete’’ letter, as long as there
continues to be no questions or
concerns about the safety of the
ingredient.
Elsewhere in this issue of the Federal
Register, we are publishing a notice of
availability for a draft guidance #293,
‘‘FDA Enforcement Policy for AAFCODefined Animal Feed Ingredients.’’ This
draft guidance communicates FDA’s
enforcement policy regarding certain
ingredients listed in chapter 6 of the
2024 AAFCO OP (or recommended by
FDA for inclusion in the AAFCO OP)
after the expiration of the Agency’s
MOU with AAFCO.
Elsewhere in this issue of the Federal
Register, we also are publishing a notice
seeking stakeholder input regarding our
current Food Additive Petition and
GRAS Notification review processes for
animal food ingredients. Additionally,
we intend to hold listening sessions and
will later provide scheduling
information for those listening sessions.
This level 1 draft guidance is being
issued consistent with FDA’s good
guidance practices regulation (21 CFR
10.115). The draft guidance, when
finalized, will represent the current
thinking of FDA on ‘‘Animal Food
Ingredient Consultation (AFIC).’’ It does
not establish any rights for any person
and is not binding on FDA or the public.
You can use an alternative approach if
it satisfies the requirements of the
applicable statutes and regulations.
II. Paperwork Reduction Act of 1995
FDA tentatively concludes that this
draft guidance contains no collection of
information subject to review and
approval by the Office of Management
and Budget (OMB) under the Paperwork
Reduction Act of 1995 (44 U.S.C. 3501–
3521), as at this time we believe that
fewer than 10 persons will avail
themselves of this process in any given
year. The draft guidance does refer to
previously approved FDA collections of
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
65369
information. The collections of
information in 21 CFR 570 have been
approved under 0910–0342; the
collections of information in 21 CFR 571
have been approved under 0910–0546.
III. Electronic Access
Persons with access to the internet
may obtain the draft guidance at https://
www.fda.gov/animal-veterinary/
guidance-regulations/guidanceindustry, https://www.fda.gov/
regulatory-information/search-fdaguidance-documents, or https://
www.regulations.gov.
Dated: August 6, 2024.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2024–17778 Filed 8–8–24; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Notice of Supplemental Award; InfantToddler Court Program—National
Resource Center
Health Resources and Services
Administration (HRSA), Department of
Health and Human Services.
ACTION: Notice of supplemental award.
AGENCY:
HRSA is providing up to
$1,750,000 in supplemental award
funds in federal fiscal year (FY) 2024 to
the current recipient of the InfantToddler Court Program (ITCP)—
National Resource Center (NRC) award,
to expand activities to help lead
nationwide improvements to child
welfare and early childhood systems.
FOR FURTHER INFORMATION CONTACT:
Kateryna Zoubak, Early Childhood
Systems Analyst, Division of Home
Visiting and Early Childhood Systems,
Maternal and Child Health Bureau,
HRSA, at ezoubak@hrsa.gov or 240–
475–8014.
SUPPLEMENTARY INFORMATION:
Intended Recipient of the Award:
ZERO TO THREE National Center for
Infant, Toddler and Families, Inc.
Amount of Non-Competitive
Award(s): One award of up to
$1,750,000.
Project Period: September 30, 2022, to
September 29, 2027.
Assistance Listing (CFDA) Number:
93.110.
Award Instrument: Non-competitive
supplemental funding to the existing
Cooperative Agreement.
Authority: 42 U.S.C. 701(a)(2) (title V,
sec. 501(a)(2) of the Social Security Act)
SUMMARY:
E:\FR\FM\09AUN1.SGM
09AUN1
Agencies
[Federal Register Volume 89, Number 154 (Friday, August 9, 2024)]
[Notices]
[Pages 65368-65369]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-17778]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2024-D-2978]
Animal Food Ingredient Consultation; Draft Guidance for Industry;
Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of availability.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing
the availability of draft guidance for industry #294 entitled ``Animal
Food Ingredient Consultation (AFIC).'' This draft guidance describes
FDA's interim AFIC process and explains one way FDA intends to work
with firms that are developing animal food ingredients after the
Memorandum of Understanding (MOU) with the Association of American Feed
Control Officials (AAFCO) expires on October 1, 2024, and while FDA
evaluates the animal Food Additive Petition and generally recognized as
safe (GRAS) Notification programs. The new AFIC process will provide an
additional way for engagement with FDA regarding ingredients for which
firms may otherwise have used the AAFCO ingredient definition process.
AFIC will help FDA identify any potential safety concerns associated
with such ingredients. The AFIC process will also allow for public
awareness of and input on such ingredients. In addition, this draft
guidance describes FDA's enforcement policy for certain ingredients
assessed using the AFIC process.
DATES: Submit either electronic or written comments on the draft
guidance by September 9, 2024 to ensure that the Agency considers your
comment on this draft guidance before it begins work on the final
version of the guidance.
ADDRESSES: You may submit comments on any guidance at any time as
follows:
Electronic Submissions
Submit electronic comments in the following way:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
Submit written/paper submissions as follows:
Mail/Hand delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2024-D-2978 for ``Animal Food Ingredient Consultation (AFIC).''
Received comments will be placed in the docket and, except for those
submitted as ``Confidential Submissions,'' publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m.
and 4 p.m., Monday through Friday, 240-402-7500.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Dockets Management Staff. If you do not wish
your name and contact information to be made publicly available, you
can provide this information on the cover sheet and not in the body of
your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852, 240-402-7500.
You may submit comments on any guidance at any time (see 21 CFR
10.115(g)(5)).
Submit written requests for single copies of the guidance to the
Policy and Regulations Staff, Center for Veterinary Medicine, Food and
Drug Administration, 7500 Standish Pl., Rockville, MD 20855. Send one
self-addressed adhesive label to assist that office in processing your
requests. See the SUPPLEMENTARY INFORMATION section for electronic
access to the draft guidance document.
FOR FURTHER INFORMATION CONTACT: Charlotte Conway, Center for
Veterinary Medicine, Food and Drug Administration, 7519 Standish Pl.,
Rockville, MD 20855, 240-402-6768, [email protected].
SUPPLEMENTARY INFORMATION:
I. Background
FDA is announcing the availability of draft guidance for industry
#294 entitled ``Animal Food Ingredient Consultation (AFIC).'' This
draft guidance describes FDA's interim AFIC process and explains one
way FDA intends to work with firms that are developing animal
[[Page 65369]]
food ingredients after the MOU with AAFCO expires on October 1, 2024,
and while FDA evaluates the animal Food Additive Petition and GRAS
Notification programs. In addition, this draft guidance describes FDA's
enforcement policy for certain ingredients reviewed using the AFIC
process.
The Food, Drug, and Cosmetic Act (FD&C Act) gives FDA the authority
to regulate substances used in animal food, including substances that
are food additives and substances that are GRAS for their intended uses
in food.\1\
---------------------------------------------------------------------------
\1\ See 21 CFR part 570, subpart E.
---------------------------------------------------------------------------
Since 1920, AAFCO has maintained the AAFCO Official Publication
(OP), which contains, among other things, a comprehensive list of
animal food ingredients, including FDA-approved food additives,
substances that are GRAS for one or more intended uses, and animal food
ingredient definitions established through the AAFCO Ingredient
Definition Request Process. In 2007, FDA entered into an MOU, 225-07-
7001, with AAFCO that outlines how FDA would provide its scientific and
technical expertise to AAFCO in reviewing requested ingredient
definitions requested by industry or AAFCO. This MOU has been renewed
and revised several times. The current MOU 225-07-7001 expires in
October 2024 and will not be renewed. See https://www.fda.gov/animal-veterinary/animal-food-feeds/fda-letter-stakeholders-acknowledgment-expiring-fda-aafco-mou.
Following the expiration of the MOU, FDA plans to evaluate its
animal Food Additive Petition and GRAS Notification programs to
determine if changes are needed to promote the efficient development
and review of new animal food ingredients.
We are issuing this draft guidance to announce the creation of the
AFIC process to provide an additional way for engagement with FDA
regarding animal food ingredients following the expiration of the MOU
with AAFCO and during this interim evaluation period. AFIC will provide
a process that will help FDA be aware of new ingredients that are
marketed in interstate commerce and any potential safety concerns
associated with such ingredients. AFIC will serve to provide a baseline
of safety information available about such an ingredient, making it
easier to compare developments that might occur during marketing. AFIC
also will give FDA an opportunity to discuss any potential safety
concerns with the developer, ideally before the ingredient is marketed.
AFIC also will allow for public awareness of and input on
ingredients for which FDA is providing consultation. Our goal is to
support innovation in animal food technologies while maintaining as our
priority the production of safe animal food.
FDA generally does not intend to initiate enforcement action with
respect to the food additive approval requirements of the FD&C Act for
an ingredient, or animal food containing such ingredient, if such an
ingredient has been reviewed and is the subject of a ``consultation
complete'' letter under the AFIC process, and is used in accordance
with the ``consultation complete'' letter, as long as there continues
to be no questions or concerns about the safety of the ingredient.
Elsewhere in this issue of the Federal Register, we are publishing
a notice of availability for a draft guidance #293, ``FDA Enforcement
Policy for AAFCO-Defined Animal Feed Ingredients.'' This draft guidance
communicates FDA's enforcement policy regarding certain ingredients
listed in chapter 6 of the 2024 AAFCO OP (or recommended by FDA for
inclusion in the AAFCO OP) after the expiration of the Agency's MOU
with AAFCO.
Elsewhere in this issue of the Federal Register, we also are
publishing a notice seeking stakeholder input regarding our current
Food Additive Petition and GRAS Notification review processes for
animal food ingredients. Additionally, we intend to hold listening
sessions and will later provide scheduling information for those
listening sessions.
This level 1 draft guidance is being issued consistent with FDA's
good guidance practices regulation (21 CFR 10.115). The draft guidance,
when finalized, will represent the current thinking of FDA on ``Animal
Food Ingredient Consultation (AFIC).'' It does not establish any rights
for any person and is not binding on FDA or the public. You can use an
alternative approach if it satisfies the requirements of the applicable
statutes and regulations.
II. Paperwork Reduction Act of 1995
FDA tentatively concludes that this draft guidance contains no
collection of information subject to review and approval by the Office
of Management and Budget (OMB) under the Paperwork Reduction Act of
1995 (44 U.S.C. 3501-3521), as at this time we believe that fewer than
10 persons will avail themselves of this process in any given year. The
draft guidance does refer to previously approved FDA collections of
information. The collections of information in 21 CFR 570 have been
approved under 0910-0342; the collections of information in 21 CFR 571
have been approved under 0910-0546.
III. Electronic Access
Persons with access to the internet may obtain the draft guidance
at https://www.fda.gov/animal-veterinary/guidance-regulations/guidance-industry, https://www.fda.gov/regulatory-information/search-fda-guidance-documents, or https://www.regulations.gov.
Dated: August 6, 2024.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2024-17778 Filed 8-8-24; 8:45 am]
BILLING CODE 4164-01-P